Our Story
Co-founded in 2017 by two pioneers in genome editing technology, Qihan Biotech has world-leading capabilities in multiplexable genome editing as well as vast experience in Immune shielding. We apply these tools in both human stem cells and animal germline cells to deliver novel immune-privileged cell and organ therapies.
ORGANS
CELLS
Kidney
Intestine
Heart
Lung
Liver
Skin
Islet cells
Cardiomyocytes
Neurons
Immune cells
Our Vision
A world in which cell and organ therapies are universally available to patients
Learn More
Our Mission
Use multiplexable genome editing in combination with extensive knowledge in transplantation immunology to create immunologically privileged allogenic cells and xenogeneic organs for use as therapies to treat cancer, organ failure and other important medical conditions
Our Science
World-leading capabilities in multiplexable gene editing
Genome editing for immune-privileged features
Learn More
Our Values
Innovation
Commitment
Integrity
Ownership
Learn More
Leadership
Board Members
Combination of Eastern and Western industry veterans and accomplished investors with successful biotech startup experience
Steven Holtzman, PhD
Luhan Yang, PhD
Neil Shen
Jake Xia, PhD
Kexiang Zhou, PhD
Bob More
Scientific Advisors
World-class scientific advisors with diverse research and clinical expertise
George Church, PhD

Co-founder and Co-Chair of Qihan scientific advisory groups

Harvard Medical SchoolMassachusetts Institute of Technology
James Markmann, MD, PhD

Co-Chair of Qihan scientific advisory groups

Center for Transplantation Sciences, Massachusetts General Hospital
Dan Kaufman, MD, PhD

Chair of Cell Therapy group

Division of Regenerative Medicine, University of California, San Diego
Zengjun Xu, MD, PhD

Former Chief Scientist of the Drug Evaluation Center of the State Drug AdministrationFormer senior review officer of FDA in US
Qizhi Tang, PhD

Surgery Division of Transplant, Transplantation Research Laboratory, University of California, San Francisco
Hiromitsu Nakauchi, MD, PhD

Institute of Stem Cell Biology and Regenerative Medicine, Stanford UniversityDivision of Stem Cell Therapy, The Institute of Medical Science, The University of Tokyo
Xin Du, PhD

Former CMC review expert of FDACEO of Shenzhen Evergreen Therapeutics Co., Ltd., CEO-Secretary General of Tongxieyi Regulation Club
Philip O'Connell, PhD

Centre for Transplant and Renal Research, The Westmead Institute for Medical Research
Jonathan Maltzman, MD, PhD

Division of Nephrology, Stanford University School of Medicine
Robert Montgomery, MD, PhD

Department of Surgery at NYU Grossman School, NYU Langone Transplant Institute
Camillo Ricordi, MD

Diabetes Research Institute and Cell Transplant Center, University of Miami
Andrew Adams, MD, PhD

Department of Surgery, Division of Transplant Surgery Clinical and Translational Research, Emory Transplant Center, Emory University School of Medicine
Investors
And More